New drug combo aims to shrink rectal tumors before surgery
NCT ID NCT04926324
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial investigates whether combining two drugs, niraparib and dostarlimab, with a short course of radiation before surgery can help treat locally advanced rectal cancer. The study first finds a safe dose of niraparib, then checks how well the combination shrinks the tumor. Participants have resectable, locally advanced rectal cancer and receive this treatment before their planned surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib and dostarlimab
What this could lead to
If successful, this combination could offer a new preoperative treatment option for locally advanced rectal cancer, potentially improving tumor shrinkage and patient outcomes.
What could go wrong
This is an early-phase trial with only 3 participants, so safety and effectiveness are not yet established. The combination may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Holden Comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa, 52242, United States